All In Biotech

Drug Trial Radar · NCT06671444

Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment

A Phase 1 Open-Label Single-Dose Study to Assess the Pharmacokinetics and Safety of YZJ-1139 in Subjects With Severe Renal Impairment and Renal Impairment

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jun 3, 2024

Primary completion

Oct 11, 2024

Study completion Nov 6, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Objective: 1. To evaluate the pharmacokinetics of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment. 2. To evaluate the safety of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment.

Conditions

  • Insomnia
  • Renal Impairment

Interventions

  • YZJ-1139Drug

    Single oral dose, 20 mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC0-t) of YZJ-1139Time frame: From Day 1 to Day 3
  2. Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of YZJ-1139Time frame: From Day 1 to Day 3
  3. Maximum Observed Plasma Concentration (Cmax) of YZJ-1139Time frame: From Day 1 to Day 3
  4. Apparent Oral Clearance (CL/F) of EntrectinibTime frame: From Day 1 to Day 3
  5. The Apparent Volume of Distribution (Vz/F) of EntrectinibTime frame: From Day 1 to Day 3
  6. Time of Maximum Observed Plasma Concentration (Tmax) of EntrectinibTime frame: From Day 1 to Day 3
  7. Apparent Terminal Elimination Half-life (t1/2) of EntrectinibTime frame: From Day 1 to Day 3
  8. Mean Residence Time (MRT0-t) of YZJ-1139Time frame: From Day 1 to Day 3
  9. Renal Excretion (Ae) of YZJ-1139Time frame: From Day 1 to Day 3
  10. renal clearance (CLR) of YZJ-1139Time frame: From Day 1 to Day 3
  11. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 7

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, China

  • The First Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.